Listen on: Spotify, Apple, or wherever you get your podcasts
Episode Description
What happens when decades of groundbreaking neuroscience challenge everything we thought we knew about depression? In this episode of Neural Compass, Dr. John Krystal—Chair of Psychiatry at Yale and the scientist whose lab discovered the rapid antidepressant effects of ketamine—joins Jimini’s Mark Jacobstein to explore how novel treatments are reshaping the future of mental health. They cover:
- The story behind ketamine’s unexpected antidepressant effects
- Why depression may be rooted in the cortex—not just monoamines
- How synaptic regrowth fuels resilience and recovery
- The promise and perils of psychedelics as clinical therapies
About Our Guest
Dr. John Krystal is a pioneering researcher best known for his lab's landmark discovery of the antidepressant effects of ketamine in patients in 2000 — work that ultimately led to major drug approvals and transformed how people receive care for treatment-resistant depression. His contributions to the neurobiology of mental health span depression, PTSD, schizophrenia, and beyond. A member of the U.S. National Academy of Medicine, Dr. Crystal holds an H-index of 178, reflecting the extraordinary reach and impact of his research.
About Our Host
Mark Jacobstein is the co-founder and president of Jimini Health. A longtime entrepreneur at the intersection of AI and health tech, he now leads Jimini’s mission to transform mental and behavioral health through clinically grounded, AI-powered care.
